Noom, the behavior change company best known for weight management, has acquired Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, in what the company calls its largest investment to date in healthy aging.
TMC offers sterile and non-sterile compounding across a broad formulary that includes men’s and women’s health, weight management, healthy aging, supplements, cosmetics, and IV therapy. Its product range includes compounded NAD+, peptides including sermorelin, topical GHK-Cu, and oxytocin. TMC serves more than 400 clinics and multiple telehealth partners from a 40,000-square-foot facility.
“Weight health is the entry point to preventive care – and foundational to healthy aging,” said Noom CEO Geoff Cook. “But it’s not the end point. This acquisition continues Noom’s expansion into healthy aging, supporting Noom’s mission to empower everyone, everywhere to live better longer. With the acquisition, we plan to broaden our formulary to include peptide-based therapies, like sermorelin, and healthy aging interventions, like NAD+, as we further expand the conditions we serve beyond weight and hormonal health.”
The women’s health relevance: by bringing compounding in-house, Noom gains the infrastructure to deliver hormonal health therapies at scale alongside its behavior change platform – a combination that could position it as a competitor to the growing number of companies offering integrated menopause, metabolic, and hormonal care (including Joi + Blokes, Wisp, and others expanding in the same direction). Compounding pharmacies have become an increasingly important channel for women’s health therapies, particularly bioidentical hormones and other personalized formulations.
TMC will continue to operate as a wholly owned subsidiary under its current leadership. Noom expects to integrate the acquisition and expand into new areas of healthy aging later this summer.
